


TTR AAVS1 Cassette
ABE9.51 Human vs Cyno



Hek293	Cassette (n=12)
hTTR EC50	3.2-4.8
cTTR EC50	6.2-8.5

FIG. 1A






FIG. 1B



TTR	PCH1 gRNA2945	PCH2 gRNA2945	PHH1 gRNA2944	PHH2 gRNA2944	PHH3 gRNA2944
EC90	3787	1922	14.98	23.83	110.5
EC90 95% CI	2135 to 8263	1339 to 2906	12.02 to 19.08	20.02 to 29.01	87.72 to 143.3
R squared	0.9758	0.9901	0.9412	0.9802	0.9918

FIG. 2A



ALAS1	PCH1 sg23	PCH2 sg23	PHH1 sg23	PHH2 sg23	PHH3 sg23
EC90	4065	1794	24.70	47.20	148.7
EC90 95% CI	2510 to 7456	1490 to 2195	22.16 to 27.70	41.11 to 54.69	130.8 to 170.6
R squared	0.9887	0.9978	0.9936	0.9951	0.9983

FIG. 2B




FIG. 3A




FIG. 3B






FIG. 3C








FIG. 3F




FIG. 4

09202023_PCH_PHH_LNP Surrogacy_Expanded doses_PC
H1_untreated_day1.png




FIG. 5A

09202023_PCH_PHH LNP Surrogacy_Expanded doses_PC H1_treated_day1.png




FIG. 5B




FIG. 6A

TTR	PCH1 gRNA2945	PCH2 gRNA2945	PCH3 gRNA2945	PHH1 gRNA2944	PHH2 gRNA2944	PHH3 gRNA2944
EC50	601.4	421.0	641.8	10.59	13.27	29.11




FIG. 6B